Gilles Besin, Ph.D., CSO at Orbital: “Elegen's unique expertise in supplying...IVT-ready synthetic DNA constructs is very attractive ...
The innovative partnership seeks to revolutionize decentralized genomic testing, offering swift turnaround times to identify individuals wh...
Within3 and Array have announced a strategic partnership integrating synchronous and asynchronous insights management. This partnership is ...
Orchard Therapeutics, now under the stewardship of Kyowa Kirin, announces a historic milestone as the U.S. Food and Drug Administration (FDA) grants approv...
QIAGEN has announced a collaborative effort with the International Panel Physicians Association (IPPA) to bolster awareness of tuberculosis (TB) screening ...
AstraZeneca has announced its definitive agreement to acquire Fusion Pharmaceuticals Inc., a trailblazing clinical-stage biopharmaceutical company speciali...
The expanded facility will focus on manufacturing therapeutic antibody drugs, contributing to the delivery of breakthrough treatments to patients globally....
The completion of Cohort 3 marks a significant milestone, with six participants receiving therapy with 67Cu-SAR-bisPSMA at the highest sing...
In an effort to bridge testing gaps and facilitate targeted therapies for EOC patients, Labcorp conducted two seminal studies, illustrating the profound im...
Biotechnology Innovation Organization (BIO), a leading lobbying group in Washington, D.C., announced its decision to sever ties with WuXi AppTec, a Chinese...
In 2023, Beckman Coulter and Fujirebio entered into a collaboration agreement focused on new biomarkers aligned with recently approved monoclonal a...
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company specializing in endocrine diseases and tumors, revealed encouraging...
Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneous...
– Proceeds will be used to complete clinical demonstration trials of the lead candidate drug RNDP-001 for the treatment of Parkinson's di...
© 2024 Biopharma Boardroom. All Rights Reserved.
